The Human Milk Oligosaccharides (HMO) Market size was estimated at $72.6 Million in 2020, projected to grow at a CAGR of 5.9% during the forecast period 2022-2027. Human Milk Oligosaccharides industry has witnessed huge demand owing to the rising customer concerns about gut health and an increase in the use of food supplements or dietary supplements. Human Milk Oligosaccharides are prebiotics that help preserve gut health in humans. They promote bacterial growth in the gut, especially in the bifidobacteria genus, that helps to boost metabolic activity. The antimicrobial and prebiotic properties of the product allows it to be used in a wide range of foods, including pharmaceutical and medicinal foods, as well as infant formulas. HMOs are sugars, the third most abundant solid after lactose and fats in human breast milk. It improves and enhances infant health by supporting immune, cognitive development, digestion and also has the potential that benefits adults. Some of the nutrition effects of HMOs found in human milk can be mimicked by commercially manufactured HMOs. HMO that is made by fermentation helps infant formula manufacturers to produce a formula that is similar to human milk than ever before, allowing formula-fed babies to reap the benefits of these vital components of breast milk. Human milk oligosaccharides have many primary roles, including infection prevention, prebiotic effects and to supply of sialic acid for brain growth. When compared to human milk, infant formulas made from bovine milk have a lower concentration of oligosaccharides. Since HMOs are beneficial to the microbiome and immunity, key players are researching and developing new techniques, such as extracting HMO from cow milk, using costly techniques or even using microbes to generate them.
The report: “Human Milk Oligosaccharides Market Forecast (2022-2027)”, by Industry ARC, covers an in-depth analysis of the following segments of the Human Milk Oligosaccharides Market.
In 2020, North America led the Human Milk Oligosaccharides Market owing to the presence of key market players and prominent baby food manufacturers in this region.
Growing consumer concerns on gut health, as well as increasing consumption of dietary supplements, are expected to propel the Human Milk Oligosaccharides Market.
The cost of production of Human Milk Oligosaccharides via chemical and enzymatic synthesis method along with the low availability of raw material are projected to restrain the market growth.
Furthermore, the lack of high-end production technology, high R&D costs, in addition to rigorous regulations is likely limit the growth of the Human Milk Oligosaccharide industry.
Based on Product, the Human Milk Oligosaccharides market is segmented into Lacto-N-neotetraose, Lacto-N-tetraose, 2'-Fucosyllactose, 3'-Fucosyllactose, 3'-Sialyllactose, 6'-Sialyllactose. Lacto-N-neotetraose accounted for the largest revenue market share in 2020 owing the rising growth of beneficial bifidobacteria and downfall in the growth of pathogenic bacteria that ultimately attracts the manufacturers of food and beverages as a result of the growing awareness that human milk oligosaccharides markets are showing amongst customers. 2'-Fucosyllactose is poised to grow with the fastest CAGR of 6.3% in the forecast period 2022-2027 as dietary supplement manufacturers shift to 2'-Fucosyllactose, since it is capable of altering gut microbiota composition and behavior from formula-powered infants receiving additional feeding, and its contribution to healthy digestion.
Based on the Application, the Human Milk Oligosaccharides market is segmented into Functional food & Beverages, Infant Formula, Food Supplements, and Others. The Infant Formula segment is accounted for the largest revenue market share in 2020 owing to HMOs' impacts, such as brain growth, infection prevention, memory enhancement, prenatal effects, and gut health maintenance. Functional foods and Beverages predicted to grow with the fastest CAGR of 6.5% in the forecast period 2022-2027 owing to the numerous health benefits offered by HMO, its use in functional food and beverage formulations is projected to increase dramatically over the forecast period, driving product demand. The use of HMOs in dietary supplements has many benefits, including improved immune, bacterial, and viral protection, improved digestion by maintaining gut health, and support for brain function.
Based on Geography, North America Human Milk Oligosaccharides Market accounted for the 39% revenue share in 2020. This is majorly attributed to the technological advancement along with the presence of key market players in this region. Growing consumer consciousness in the area, one of the main factors helping the business in the country to expand further with numerous product launches is the health benefits of HMO. In 2016 for instance, Jennewein Biotechnologie GmbH developed 2'-fucosylactose as a food grade quality commodity for the first time to satisfy the requirements of the US market for a formula for children. HMO market is expected to expand in the region with the growing incorporation of HMO into the prebiotics as it helped to establish commensal bacteria and increased demand for functional foods and beverages and dietary supplements for improving health and digestions. The asia-Pacific market is poised to grow with the fastest CAGR in the forecast period 2022-2027 owing its increase in the aging population. According to the World Health Organization, the global population is estimated to grow by around 1 billion in the next ten years, reaching 9.5 billion by 2050. The demand for infant nutrition products is expected to rise as the world's population continues to expand. Owing to the large number of infants in China and other Asia Pacific countries, the demand for infant formula is extremely strong.
Owing to the concerns about child malnutrition and mortality around the world, demand for HMO in infant formula is accelerating the market growth. Human milk oligosaccharides (HMO) have prebiotic properties, the potential to improve memory and brain growth, and a high nutritional value, all of which drive consumer demand (HMO). The breast milk's ability to protect babies from infection and protect them against allergic reactions would influence the market size. It appears that human milk provides long-term defense against obesity, hypertension, auto-immune, diabetes and heart diseases to human beings. The compound also prevents the attachment of microbes to the gut, pathogens which organic acids, and helps to reduce inflammation and thereby drive business trends. The substance contributes to gut health by increasing the synthesis of short-chain fatty acids - a primary energy source for enterocytes and a principal molecule for the preservation of intestinal health.
The third largest portion of human milk is human oligosaccharides that cannot be synthesized directly by means of human milk as the donor group is in limited supply. Currently, manufacturers are using chemical and enzyme synthesis for the production of human milk oligosaccharides. These methods require high resources and money, but the final output product is relatively small. For example, expensive substrates such as glycosyl transferases require enzyme synthesis and this is one of the main factors attributable to the high pricing of human milk oligosaccharides. Prebiotics in infant formula, such as fructooligosaccharides and galactooligosaccharides, are used to inhibit the development of pathogenic Escherichia coli. Consumption of these has been shown to improve the health of infants' gastrointestinal tracts by promoting the development of specific microorganisms in the intestinal microflora. Owing to their low cost and wide availability, these are being used as a replacement for human milk oligosaccharides by infant formula manufacturers. As a result, these functionally equivalent alternatives to human milk oligosaccharides are severely limiting the overall market's expansion.
Product launches, mergers and acquisitions, joint ventures and geographical expansions are key strategies adopted by players in the Human Milk Oligosaccharides Market. Human Milk Oligosaccharides Market top 10 companies are ZuChem, Inc., Elicityl SA, Jennewein Biotechnologie GmbH, Inbiose, Glycosyn LLC, Medolac Laboratories, Glycom A/S, Nestle Nutrition, DuPont Nutrition, BASF SE.
In May 2019, BASF SE and Glycosyn LLC has signed an agreement to develop and commercialize HMO for use in dietary supplements, functional nutrition, and medicinal food. BASF SE expands its offering of the most abundant HMO, 2'-Fucosyllactose (2'-FL) labelled PREBILACTM, to emerging markets as part of the partnership and under the exclusive license.
This product will be delivered within 2 business days.
Report Coverage
The report: “Human Milk Oligosaccharides Market Forecast (2022-2027)”, by Industry ARC, covers an in-depth analysis of the following segments of the Human Milk Oligosaccharides Market.
- By Product: Lacto-N-neotetraose, Lacto-N-tetraose , 2'-Fucosyllactose, 3'-Fucosyllactose, 3'-Sialyllactose, 6'-Sialyllactose.
- By Application: Food Supplements, Functional food & Beverages, Infant Formula, and Others.
- By Type: Acidic, Neutral.
- By Geography: North America (U.S., Canada, Mexico), Europe (Germany, U.K., France, Spain, Italy, Russia and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia & New Zealand, and Rest of Asia Pacific), South America (Brazil, Argentina and Rest of South America), and Rest of the World (the Middle East and Africa).
Key Takeaways
In 2020, North America led the Human Milk Oligosaccharides Market owing to the presence of key market players and prominent baby food manufacturers in this region.
Growing consumer concerns on gut health, as well as increasing consumption of dietary supplements, are expected to propel the Human Milk Oligosaccharides Market.
The cost of production of Human Milk Oligosaccharides via chemical and enzymatic synthesis method along with the low availability of raw material are projected to restrain the market growth.
Furthermore, the lack of high-end production technology, high R&D costs, in addition to rigorous regulations is likely limit the growth of the Human Milk Oligosaccharide industry.
Human Milk Oligosaccharides Market Segment Analysis - By Product
Based on Product, the Human Milk Oligosaccharides market is segmented into Lacto-N-neotetraose, Lacto-N-tetraose, 2'-Fucosyllactose, 3'-Fucosyllactose, 3'-Sialyllactose, 6'-Sialyllactose. Lacto-N-neotetraose accounted for the largest revenue market share in 2020 owing the rising growth of beneficial bifidobacteria and downfall in the growth of pathogenic bacteria that ultimately attracts the manufacturers of food and beverages as a result of the growing awareness that human milk oligosaccharides markets are showing amongst customers. 2'-Fucosyllactose is poised to grow with the fastest CAGR of 6.3% in the forecast period 2022-2027 as dietary supplement manufacturers shift to 2'-Fucosyllactose, since it is capable of altering gut microbiota composition and behavior from formula-powered infants receiving additional feeding, and its contribution to healthy digestion.
Human Milk Oligosaccharides Market Segment Analysis - By Application:
Based on the Application, the Human Milk Oligosaccharides market is segmented into Functional food & Beverages, Infant Formula, Food Supplements, and Others. The Infant Formula segment is accounted for the largest revenue market share in 2020 owing to HMOs' impacts, such as brain growth, infection prevention, memory enhancement, prenatal effects, and gut health maintenance. Functional foods and Beverages predicted to grow with the fastest CAGR of 6.5% in the forecast period 2022-2027 owing to the numerous health benefits offered by HMO, its use in functional food and beverage formulations is projected to increase dramatically over the forecast period, driving product demand. The use of HMOs in dietary supplements has many benefits, including improved immune, bacterial, and viral protection, improved digestion by maintaining gut health, and support for brain function.
Human Milk Oligosaccharides Market Segment Analysis - By Geography:
Based on Geography, North America Human Milk Oligosaccharides Market accounted for the 39% revenue share in 2020. This is majorly attributed to the technological advancement along with the presence of key market players in this region. Growing consumer consciousness in the area, one of the main factors helping the business in the country to expand further with numerous product launches is the health benefits of HMO. In 2016 for instance, Jennewein Biotechnologie GmbH developed 2'-fucosylactose as a food grade quality commodity for the first time to satisfy the requirements of the US market for a formula for children. HMO market is expected to expand in the region with the growing incorporation of HMO into the prebiotics as it helped to establish commensal bacteria and increased demand for functional foods and beverages and dietary supplements for improving health and digestions. The asia-Pacific market is poised to grow with the fastest CAGR in the forecast period 2022-2027 owing its increase in the aging population. According to the World Health Organization, the global population is estimated to grow by around 1 billion in the next ten years, reaching 9.5 billion by 2050. The demand for infant nutrition products is expected to rise as the world's population continues to expand. Owing to the large number of infants in China and other Asia Pacific countries, the demand for infant formula is extremely strong.
Human Milk Oligosaccharides Market Segment Analysis-Drivers
Demand for HMO in Infant Formula
Owing to the concerns about child malnutrition and mortality around the world, demand for HMO in infant formula is accelerating the market growth. Human milk oligosaccharides (HMO) have prebiotic properties, the potential to improve memory and brain growth, and a high nutritional value, all of which drive consumer demand (HMO). The breast milk's ability to protect babies from infection and protect them against allergic reactions would influence the market size. It appears that human milk provides long-term defense against obesity, hypertension, auto-immune, diabetes and heart diseases to human beings. The compound also prevents the attachment of microbes to the gut, pathogens which organic acids, and helps to reduce inflammation and thereby drive business trends. The substance contributes to gut health by increasing the synthesis of short-chain fatty acids - a primary energy source for enterocytes and a principal molecule for the preservation of intestinal health.
Human Milk Oligosaccharides Market Segment Analysis-Challenges
High Cost of Production:
The third largest portion of human milk is human oligosaccharides that cannot be synthesized directly by means of human milk as the donor group is in limited supply. Currently, manufacturers are using chemical and enzyme synthesis for the production of human milk oligosaccharides. These methods require high resources and money, but the final output product is relatively small. For example, expensive substrates such as glycosyl transferases require enzyme synthesis and this is one of the main factors attributable to the high pricing of human milk oligosaccharides. Prebiotics in infant formula, such as fructooligosaccharides and galactooligosaccharides, are used to inhibit the development of pathogenic Escherichia coli. Consumption of these has been shown to improve the health of infants' gastrointestinal tracts by promoting the development of specific microorganisms in the intestinal microflora. Owing to their low cost and wide availability, these are being used as a replacement for human milk oligosaccharides by infant formula manufacturers. As a result, these functionally equivalent alternatives to human milk oligosaccharides are severely limiting the overall market's expansion.
Human Milk Oligosaccharides Market Segment Landscape:
Product launches, mergers and acquisitions, joint ventures and geographical expansions are key strategies adopted by players in the Human Milk Oligosaccharides Market. Human Milk Oligosaccharides Market top 10 companies are ZuChem, Inc., Elicityl SA, Jennewein Biotechnologie GmbH, Inbiose, Glycosyn LLC, Medolac Laboratories, Glycom A/S, Nestle Nutrition, DuPont Nutrition, BASF SE.
Acquisitions/Product Launches:
In May 2019, BASF SE and Glycosyn LLC has signed an agreement to develop and commercialize HMO for use in dietary supplements, functional nutrition, and medicinal food. BASF SE expands its offering of the most abundant HMO, 2'-Fucosyllactose (2'-FL) labelled PREBILACTM, to emerging markets as part of the partnership and under the exclusive license.
This product will be delivered within 2 business days.
Table of Contents
1. Human Milk Oligosaccharides Market - Overview
2. Human Milk Oligosaccharides Market - Executive Summary
3. Human Milk Oligosaccharides Market - Comparative Analysis
4. Human Milk Oligosaccharides Market Forces
5. Human Milk Oligosaccharides Market - Strategic Analysis
6. Human Milk Oligosaccharides Market - By Product (Market Size -$Million/$Billion)
7. Human Milk Oligosaccharides Market - By Application (Market Size -$Million/$Billion)
8. Human Milk Oligosaccharides Market - By Type(Market Size -$Million/$Billion)
9. Human Milk Oligosaccharides Market - By Geography(Market Size -$Million/$Billion)
11. Human Milk Oligosaccharides Market Company Analysis
Methodology
LOADING...
